The role of DNA methylation in musculoskeletal diseases is poorly understood. Results: Methylation of specific CpG sites in the MMP13 and IL1B promoters correlates strongly with gene activity in human cartilage. Conclusion: Specific CpG site methylation inhibits MMP13 transactivation by HIF-2␣. Significance: Our findings offer new insight on the impact of epigenetic control of a joint disease that can affect adults throughout life.
The role of DNA methylation in the regulation of catabolic genes such as MMP13 and IL1B, which have sparse CpG islands, is poorly understood in the context of musculoskeletal diseases. We report that demethylation of specific CpG sites at ؊110 bp and ؊299 bp of the proximal MMP13 and IL1B promoters, respectively, detected by in situ methylation analysis of chondrocytes obtained directly from human cartilage, strongly correlated with higher levels of gene expression. The methylation status of these sites had a significant impact on promoter activities in chondrocytes, as revealed in transfection experiments with site-directed CpG mutants in a CpG-free luciferase reporter. Methylation of the ؊110 and ؊299 CpG sites, which reside within a hypoxia-inducible factor (HIF) consensus motif in the respective MMP13 and IL1B promoters, produced the most marked suppression of their transcriptional activities. Methylation of the ؊110 bp CpG site in the MMP13 promoter inhibited its HIF-2␣-driven transactivation and decreased HIF-2␣ binding to the MMP13 proximal promoter in chromatin immunoprecipitation assays. In contrast to HIF-2␣, MMP13 transcriptional regulation by other positive (RUNX2, AP-1, ELF3) and negative (Sp1, GATA1, and USF1) factors was not affected by methylation status. However, unlike the MMP13 promoter, IL1B was not susceptible to HIF-2␣ transactivation, indicating that the ؊299 CpG site in the IL1B promoter must interact with other transcription factors to modulate IL1B transcriptional activity. Taken together, our data reveal that the methylation of different CpG sites in the proximal promoters of the human MMP13 and IL1B genes modulates their transcription by distinct mechanisms.
Somatic cell phenotypes can be stably regulated by epigenetic mechanisms, including DNA methylation (1, 2) , which may regulate gene transcription by recruiting chromatin remodeling proteins and by modulating the binding affinities of specific transcription factors (3) (4) (5) (6) (7) . In contrast to the more dynamic and reversible histone modifications (1), CpG methylation is generally stable in somatic cells throughout adult life (8, 9) . Investigations have mainly focused on the so-called CpG islands but have ignored the contributions of sparse CpG sites. Moreover, only a few reports have addressed how methylation of individual CpG sites influences the promoter activity of a specific gene (6, 10, 11) , and the relative contributions of the methylation status of each individual CpG site to the transcriptional regulation of a given gene in vivo remain largely unexplored. In addition, although epigenetic gene regulation has been broadly investigated in other contexts, little is known about the specific impact of this mechanism of gene control in musculoskeletal diseases (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) .
Osteoarthritis (OA) 3 is characterized by the progressive loss of cartilage matrix, accompanied by deleterious changes in the synovium and subchondral bone (30, 31) . In OA disease, chondrocytes undergo phenotypic changes with altered patterns of gene expression that are stably transmitted to subsequent cell generations (25, 32) , suggesting the involvement of epigenetic mechanisms in disease onset and progression. We previously described a novel relationship between CpG demethylation within the CpG-sparse promoters of the MMP3, -9, -13, and ADAMTS4 genes and their aberrant, enhanced expression in OA chondrocytes, although a direct relationship between the methylation status of a specific CpG site and the respective promoter activity was not investigated (25) . We also found that long term, repetitive stimulation of primary human chondrocytes with inflammatory cytokines induced demethylation of specific CpG sites in the IL1B proximal promoter, leading to increased and sustained IL1B expression (22) . More recently, Reynard et al. (24) reported CpG methylation-dependent regulation of growth differentiation factor 5 expression in OA, along with direct evidence of suppressed gene activity in response to methylation of its CpG islands in vitro.
Here, we report that the methylation of specific CpG sites in the proximal promoters of both the human MMP13 and IL1B genes correlates with their expression in cartilage and alters their transcriptional activities in chondrocytes. In addition, we provide the first evidence that binding to and transactivation of the MMP13 promoter by hypoxia-inducible factor-2␣ (HIF-2␣), also known as EPAS1 (endothelial PAS domain protein 1), are controlled by these epigenetic events. Importantly, our in vitro results correlate strongly with the in vivo methylation status of the same individual CpG sites in the MMP13 and IL1B promoters and with their relative levels of gene activity in chondrocytes isolated directly from healthy and OA human cartilage.
EXPERIMENTAL PROCEDURES
Human Primary Chondrocyte Isolation-Human articular cartilage was obtained after hemiarthroplasty following femoral neck fracture or total hip arthroplasty for OA with patient consent and prior approval of the local Institutional Review Board. Cartilage was dissected within 6 h of surgery, and non-OA fractured neck of femur and OA human primary chondrocytes were isolated as described previously (22) . Briefly, samples were obtained from the deep zone of cartilage from patients with femoral neck fracture for isolation of non-OA/healthy chondrocytes, whereas cartilage pieces adjacent to weight-bearing areas of OA femoral heads (lacking surface zones) were harvested to obtain OA chondrocytes. Cartilage samples were then cut in small fragments and digested with 10% trypsin (Lonza) in PBS for 30 min, followed by sequential digestions in 1 mg/ml of hyaluronidase (Sigma-Aldrich) in PBS for 15 min, and in 10 mg/ml of collagenase B (Roche Applied Science) in ␣-modified Eagle's medium (SigmaAldrich) for 12-15 h at 37°C. Following isolation, the chondrocytes were either subjected to bisulfite pyrosequencing or placed in primary culture.
Pyrosequencing-Genomic DNA extracted directly from neck of femur and OA chondrocytes or from cultured chondrocytes was treated with sodium bisulfite to convert unmethylated cytosine in CpG sites to uracil using the EZ DNA methylation Gold kit (Zymo Research). PCR and sequencing primers for pyrosequencing were designed using the Biotage Assay Design Software (version 2.0; Table 1) . PCR was performed with Premium® PCR Supermix High Fidelity (Invitrogen). Pyrosequencing reactions were run in the PyroMark Q96 MD system (Qiagen), using 20 l and 5 l of the PCR products for CpG methylation analysis of MMP13 and IL1B promoters, respectively. Data are represented as percentage of methylation of each CpG site in OA or 5-aza-deoxycytidine (5-aza-dC)-treated samples set against 100% in the non-OA or untreated controls.
Human Primary Chondrocyte Culture and 5-Aza-dC Treatment-For culture and in vitro analysis, only deep-zone primary non-OA chondrocytes were utilized, as described (21) . Before treatment, chondrocytes were cultured for 48 h at an average density of 16 ϫ 10 3 cells/cm 2 in a 25-cm 2 flask in 5 ml of ␣-modified Eagle's medium supplemented with 10% FBS (Invitrogen), 1% insulin-transferrin-selenium (Sigma-Aldrich), 100 units/ml of penicillin, and 100 g/ml of streptomycin (Lonza) and 100 g/ml of ascorbic acid (Sigma-Aldrich). The chondrocytes were then left untreated (control) or incubated with 2 M 5-aza-dC and added freshly at twice weekly medium changes for 4 to 5 weeks until confluence. DNA and RNA Extraction-Genomic DNA and total RNA were extracted simultaneously from the harvested chondrocytes using AllPrep DNA/RNA mini kit (Qiagen). RNA was reverse-transcribed with avian myeloblastosis virus reverse transcriptase and combination of oligo(dT) 15 and random primers (Promega).
Quantitative RT-PCR-Gene expression was analyzed with the ABI Prism 7500 gene detection system (Applied Biosystems) using the following primers, designed using Primer Express software (version 3.0; Applied Biosystems) to bracket exon-exon boundaries: GAPDH, 5Ј-CCAGGTGGTCTCCTCTGACTTC-3Ј (forward) and 5Ј-TCATACCAGGAAATGAGCTTGACA-3Ј (reverse); MMP13, 5Ј-TTAAGGAGCATGGCGACTTCT-3Ј (forward) and 5Ј-CCCAGGAGGAAAAGCATGAG-3Ј (reverse). The IL1B primers were designed by and purchased from PrimerDesign, Ltd. (Southampton, UK): 5Ј-TGGCAATGA-GGATGACTTGTTC-3Ј (forward) and 5Ј-CTGTAGTGGT-GGTCGGAGATT-3Ј (reverse). Reactions were performed in triplicate, with GAPDH as the normalizing control gene. The 2
Ϫ⌬⌬Ct method was employed for relative quantification.
Plasmid Constructions-A CpG-free reporter vector, pCpGfree-Luc vector, was generated according to the literature (33) . The MMP13 promoter constructs spanning Ϫ372/ϩ14, Ϫ214/ ϩ14, and Ϫ86/ϩ14 bp of the human MMP13 promoter sequence and containing seven, four, and one CpG sites, respectively, were generated by PCR amplification, utilizing genomic DNA from the human chondrocyte cell line C28/I2 (34) as a template and the following PCR primers: MMP13(Ϫ372/ϩ14), 5Ј-CCGACTAGTGGAAGTAAACATGCCATCTTGATA-3Ј (forward); MMP13(Ϫ214/ϩ14), 5Ј-CCGACTAGTATTTTG-CCAGATGGGTTTTG-3Ј (forward); MMP13(Ϫ86/ϩ14), forward: 5Ј-CCGACTAGTCAAGTGACTAGGAAGTGGAA-ACC-3Ј; and reverse (common to all three MMP13 promoter constructs): 5Ј-CCGAAGCTTCCTGGGGACTGTTGTC-TTT-3Ј. Underlined letters indicate SpeI and HindIII recognition sequences in the forward and reverse primers, respectively. The resultant PCR products were digested with SpeI and HindIII and transferred into the multiple cloning site of a pCpGfree-Luc vector treated with the same enzymes using TaKaRa DNA ligation kit (version 2.1; TaKaRa).
The human IL1B promoter constructs spanning Ϫ521/ϩ56, Ϫ276/ϩ56, and Ϫ183/ϩ56 bp and containing four, three, and two CpG sites, respectively, were generated by PCR amplification utilizing the following PCR primers: IL1B(Ϫ521/ϩ56), 5Ј-CCGACTAGTAGAGAGCTCCTGAGGCAGAG-3Ј (forward); IL1B(Ϫ276/ϩ56), 5Ј-CCGACTAGTTGTGGACATCAACTGC-ACAA-3Ј (forward); IL1B(Ϫ183/ϩ56), 5Ј-CCGACTAGTCCCT-TCCATGAACCAGAGA-3Ј (forward); and common to all three IL1B promoter constructs, 5Ј-CCGAGATCTGGCTGAAGAG-AATCCCAGAG-3Ј (reverse). Underlined letters indicate SpeI and BglII recognition sequences on the forward and reverse primers, respectively. The resultant PCR products were digested with SpeI and BglII and transferred into the multiple cloning site of the pCpGfree-Luc vector.
Point mutations of CpG sites were generated by converting CG to TG by a two-step PCR mutagenesis approach as described previously (35) using the primers shown in Table 2 and the wild type (WT) Ϫ214/ϩ14 bp MMP13 (MMP13-214) or Ϫ521/ϩ56 bp IL1B (IL1B-521) promoter constructs, linearized by double enzyme digestion by SacI and KpnI as templates. After two-step PCR, the resulting products were digested with SpeI/HindIII and SpeI/BglII for MMP13-214 and IL1B-521, respectively, and cloned into the pCpGfree-Luc vector backbone treated with the same enzymes using TaKaRa DNA ligation kit (version 2.1, TaKaRa). Promoter constructs with multiple CpG mutations were generated by a repeated two-step PCR mutagenesis, utilizing different PCR mutagenesis primers and linearized CpG-mutated MMP13-214 or IL1B-521 construct as template. Expression vectors encoding ELF3, HIF1␣, HIF-2␣, Sp1, RUNX2, NF-B, and AP-1 (cFos/cJun) were purchased from Addgene and/or described elsewhere (35) (36) (37) . The sequences of all constructs were confirmed by DNA sequencing at the Cornell University Life Sciences Core Laboratories Center.
In Vitro Methylation, Transfections, and Luciferase AssayThe methylated plasmids were generated by incubating 1 g of plasmid DNA with 4 units/l of the CpG methyltransferase, M.SssI (Zymo Research) in reaction buffer supplemented with 1600 M S-adenosylmethionine according to the manufacturer's instructions. Complete methylation was verified by plasmid DNA bisulfite modification and pyrosequencing using specific primers. The methylated plasmid DNA was purified by the PureLink Quick Plasmid Miniprep kit (Invitrogen). The methylated and non-methylated vectors were then transfected in immortalized human chondrocytes (C28/I2) seeded 24 h prior to transfection in 24-well tissue culture plates at 3.0 ϫ 10 4 cells/well, using Lipofectamine PLUS TM reagents as described (35) . Briefly, transfections were carried out in triplicate in serum-free antibiotic-free conditions, with a total of no more than 475 ng of plasmid DNA per well, including 300 ng of non-methylated or methylated MMP13 or IL1B luciferase reporter construct and the expression vectors. The ratios of luciferase reporter construct to expression vector were established by titrations to ensure that concentrations of expressed transcription factors were not limiting to the promoter transactivations under the conditions of the co-transfections. Reporter constructs were treated with DNA methyltransferase to methylate all available CpG sites in the promoters. Luciferase assays were performed using the luciferase assay system (Promega) and detected using a LMaxII 384 Luminometer system (Molecular Devices). Unless otherwise specified, the firefly luciferase activities were normalized to the Renilla activity of pGL4.74-hRluc-TK (Promega).
ChIP Assay-The ChIP-IT Express Enzymatic Kit (ActiveMotif) was used to perform ChIP assays according to the manufacturer's instructions with minor modifications, as described (35) , using C28/I2 chondrocytic cells co-transfected with nonmethylated or methylated pCpGfree-Luc-MMP13 vector (Ϫ214/ϩ14bp) and expression vectors encoding HA-tagged HIF-2␣ or FLAG-tagged ELF3. At 24 h after transfection, precleared chromatin was stored as assay input or incubated at 4°C overnight with 1.25 g of rabbit anti-HA antibody (Invitrogen), rabbit anti-FLAG antibody (Sigma), or normal rabbit IgG (Cell Signaling). After reverse cross-linking and purification on DNA mini-columns (Qiagen), the final DNA preparations were subjected to quantitative PCR analysis using 5 l of the eluted DNA and the following primers specific for the transiently trans-fected MMP13 reporter construct: 5Ј-TCAAATTCTACCAC-AAACCACA-3Ј (forward) and 5Ј-TAATATTCTTGGCAT-CCTCCAT-3Ј (reverse). Primer efficiency was calculated utilizing serial dilutions of the pooled input DNA samples. For real time PCR analysis, the C T of each sample was normalized to the C T of the input sample (10%).
Statistical Analysis-Each data point is reported as the means Ϯ S.E. of at least three independent experiments. Statistical significance was evaluated using Student's t test, with p values of Ͻ 0.05 considered significant.
RESULTS

Specific MMP13 and IL1B Proximal Promoter CpG Sites Are Demethylated in OA Chondrocytes and Correlate with Higher
Levels of Gene Expression in OA Disease-We initially quantified the CpG methylation status of the Ϫ343/Ϫ14 bp MMP13 and Ϫ299/ϩ13 bp IL1B proximal promoter sequences in human primary chondrocytes isolated from articular cartilage obtained from non-OA donors (n ϭ 12) and patients with OA (n ϭ 17). Pyrosequencing analysis of the MMP13 promoter revealed that five of the seven CpG sites contained in the proximal promoter region were significantly demethylated in OA compared with non-OA chondrocytes. The highest degree of demethylation was observed at the Ϫ110-bp CpG site (Fig. 1A) . The IL1B promoter was also significantly demethylated at the Ϫ299-bp CpG and Ϫ256-bp CpG sites in OA compared with non-OA chondrocytes, whereas there was no significant difference in methylation status at the Ϫ20-bp CpG and ϩ13-bp CpG sites (Fig. 1B) . Finally, the decreased methylation of the MMP13 (Fig. 1C) and IL1B (Fig. 1D) proximal promoters correlated with higher levels of their mRNAs in OA chondrocytes (Fig. 1C) .
CpG Demethylation in Vitro Correlates with Enhanced Levels of MMP13 and IL1B Gene Expression in Cultured Human
Primary Chondrocytes-To determine the functional effects of demethylating the CpG sites in the MMP13 and IL1B promoters, we cultured human primary chondrocytes in the presence or absence of 5-aza-dC, a CpG demethylating agent, as described (22) . Treatment with 5-aza-dC resulted in significant demethylation of the CpG sites in the MMP13 promoter at Ϫ343 bp, Ϫ115 bp, Ϫ110 bp, and Ϫ14 bp ( Fig. 2A) . In the IL1B promoter, significant loss of methylation occurred at the Ϫ299 bp CpG after 5-aza-dC treatment (Fig. 2B ). In accordance with these results, we had reported previously that MMP13 and IL1B mRNA levels increased by 2-and 5-fold, respectively, in response to treatment with 5-aza-dC (22, 38) .
Methylation of Unique CpG Sites in the Proximal Human MMP13 and IL1B Gene Promoters Directly Affects
Transcriptional Activities-We next investigated the contribution of each of the methylation-sensitive CpG sites to MMP13 and IL1B promoter activities using a CpG-free reporter system. The activities of deletion constructs of the MMP13 promoter, spanning Ϫ372/ϩ14, Ϫ214/ϩ14, and Ϫ86/ϩ14 bp, were significantly reduced in their methylated state (Fig. 3A) . Next, we generated mutant constructs of the Ϫ214/ϩ14-bp MMP13 promoter harboring site-specific CpG mutation(s), replacing unique cytosine (C) with thymine (T) residues, as indicated in Fig. 3B . A single CpG mutation at Ϫ110 bp (Ϫ110 mt) significantly decreased promoter activity compared with the WT promoter; in contrast, no other individual CpG mutant caused a significant change in MMP13 promoter activity. In addition, methylation significantly suppressed the activities of all single CpG mutants except for the Ϫ110 mt and Ϫ14 mt (Fig. 3B) . Moreover, a triple CpG mutant construct (Ϫ135/Ϫ115/Ϫ14 mt), which preserves the Ϫ110 bp CpG site, retained promoter activity comparable with WT; all other triple mutants with a mutated Ϫ110 bp CpG site showed significantly decreased promoter activity (Fig. 3C) . Importantly, CpG methylation treatment of the Ϫ135/Ϫ115/Ϫ14-mt construct significantly decreased reporter activity. These results indicate that the methylation status of the Ϫ110-bp CpG is crucial for MMP13 promoter activity. In contrast, activity of the methylated Ϫ135/ Ϫ110/Ϫ14-mt construct, which only preserves the Ϫ115-bp CpG site, increased by 3.7-fold (Fig. 3C) .
We also generated three IL1B promoter constructs. Methylation treatment significantly decreased the activities of the WT Ϫ521/ϩ56 and Ϫ276/ϩ56 reporter constructs, with no significant effect on the Ϫ183/ϩ56-bp promoter (Fig. 3D ). Single and triple CpG mutant constructs of the Ϫ521/ϩ56 WT IL1B promoter revealed that a single CpG mutation at Ϫ299 bp (Ϫ299 mt) significantly decreased promoter activity, whereas the Ϫ256-bp CpG mutant was significantly more active than WT; mutations of the other two CpG sites had no effect on promoter activity (Fig. 3E) . Among the triple CpG mutants with only one intact CpG site, the basal activity of the Ϫ256/Ϫ20/ϩ13-mt promoter did not change, whereas the basal activities of all constructs containing a mutated Ϫ299-bp CpG decreased significantly (Fig. 3F) . Furthermore, methylation treatment significantly decreased the activity of the Ϫ256/Ϫ20/ϩ13 mutant (Fig. 3F) . These results indicate that, similar to the Ϫ110-bp CpG site in the MMP13 promoter, the methylation status of one CpG at Ϫ299 bp in the IL1B promoter uniquely impacts on its transcriptional activity.
CpG Methylation Impairs HIF-2␣-driven MMP13 Promoter Transactivation but Not IL1B Promoter Activation-CpG methylation may regulate gene transcriptional activities by differentially and directly modulating the binding affinities of trans-acting factors (6). Hence, we next investigated the effects of CpG methylation status on the actions of MMP13 transacting factors selected based on previous reports (35, 39 -44) and on bioinformatic analyses using the Transcription Element Search System (Fig. 4A ). In agreement with prior work (43, 44) , HIF-2␣ overexpression increased the activity of the nonmethylated WT Ϫ214/ϩ14-bp promoter construct; interestingly, CpG methylation significantly attenuated this HIF-2␣-mediated promoter activation (Fig. 4B) . In addition, HIF-2␣ overexpression did not significantly activate the nonmethylated Ϫ110-mt construct (Fig. 4B) , whereas HIF-2␣ transactivated the non methylated triple mutant with an intact Ϫ110-bp CpG to an extent comparable with the WT construct. All other triple mutant constructs showed decreased HIF-2␣-driven transactivation, compared with the WT reporter construct (Fig. 4C) . Methylation treatment of the triple mutant with an intact Ϫ110-bp CpG significantly decreased MMP13 promoter activity in response to HIF-2␣ overexpression (Fig. 4C) . Together, these results indicate that targeted Ϫ110-bp CpG methylation 
impairs HIF-2␣ transactivation of the MMP13 promoter in vitro.
To assess the specificity of the above effects of HIF-2␣, we interrogated the dependence of activities of multiple transcription factors on CpG site-specific methylation of the MMP13 promoter. Overexpression of RUNX2, ELF3, or AP-1 (c-Fos/cJun) activated the MMP13 promoter constructs as shown previously (35, 42) ; but in contrast to our results with HIF-2␣, these transactivations were unaffected by any CpG site mutation or by alteration of methylation status (data not shown). Moreover, in contrast to HIF-2␣, HIF-1␣ had no significant effect when co-transfected with any MMP13 promoter construct in the absence or presence of methylation (data not shown). Similarly, overexpressing Sp1, USF-1, or GATA-1 had no effect on MMP13 promoter activity and did not correlate with mutation or methylation of any specific CpG site (data not shown).
We also investigated the effects of CpG methylation on the actions of candidate IL1B trans-acting factors (Fig. 4D) . HIF-2␣ overexpression had no significant effect on IL1B promoter activity (Fig. 4, E and F) . In contrast, HIF-1␣ or NF-B (p65/ p50) overexpression significantly increased IL1B promoter activity, but this enhancement was independent of mutation of any CpG site or alteration of CpG methylation status (data not shown). Furthermore, overexpression of USF-1 or the combi- nation of Single-minded (Sim) 2 and aryl hydrocarbon receptor nuclear translocator (ARNT) significantly repressed IL1B promoter activity, but the latter responses were not significantly changed by the methylation status of the promoter or by targeted mutation of any CpG site (data not shown).
CpG Methylation Attenuates HIF-2␣ Binding to the MMP13 Promoter-Given the results above, we investigated whether CpG methylation status directly affected HIF-2␣ binding to the proximal MMP13 promoter in ChIP assays. In the context of endogenous chromatin, methylating/demethylating agents would impact transcription affecting not only in the proximal promoter region analyzed in our study but also distal sequences, therefore introducing further complexity to the analysis. Hence, to avoid confounding effects of CpG sites in distal MMP13 promoter regions and their contributions to overall endogenous chromatin structure, ChIP assays were performed in chondrocytes transfected with methylated and nonmethylated WT Ϫ214/ϩ14-bp MMP13 constructs in combination with expression vectors encoding HA-tagged HIF-2␣ or FLAG-tagged ELF3; and MMP13 promoter binding was analyzed with specific PCR primers that only recognize the transiently transfected promoter constructs, as described in the "Experimental Procedures." ChIP assays revealed that methylation treatment significantly reduced HIF-2␣ binding to the MMP13 proximal promoter (Fig. 5A ), in agreement with our results showing decreased HIF-2␣-driven MMP13 transactivation after methylation treatment of the WT and/or mutant MMP13 reporter constructs (Fig. 4, B and C) . In contrast, as a control, ELF3 binding to the proximal MMP13 promoter was not affected by promoter methylation status (Fig. 5B ), in accordance with our results showing that ELF3-driven MMP13 transactivation is methylation-insensitive, as indicated above. Our results show that CpG methylation of the MMP13 proximal promoter specifically impairs HIF-2␣-driven promoter activation by altering its binding to DNA.
DISCUSSION
MMP-13, or collagenase 3, is the major type II collagen-degrading enzyme that drives erosion of the cartilage collagen network in OA disease (45) (46) (47) (48) . This enzyme plays essential roles in extracellular matrix remodeling in the late hypertrophic zone of the growth plate prior to endochondral ossification, but articular chondrocytes express low basal MMP-13 levels under normal, physiological conditions in vivo (49) . High levels and activity of MMP-13 and other matrix-degrading enzymes in OA chondrocytes are due in part to their activated state in response to enhanced stress and inflammatory signaling (reviewed in Ref. 39 ). MMP13 transcription is subject to regulation by a number of transcription factors, including ELF3, RUNX2, AP-1 (cFos/cJun), p130 cas nuclear matrix transcription factor 4 (NMP-4), the canonical NF-B subunits p65/ p50, and HIF-2␣ (35, 40 -44, 50) . NF-B also plays a major role in increased IL1B expression in various cell types under stress/ proinflammatory conditions by directly activating the IL1B promoter (51, 52) . Moreover, as shown previously, NF-B modulates gene expression in some contexts via epigenetic mechanisms, affecting the level of CpG demethylation (53).
Our previous studies showed epigenetic changes associated with abnormal MMP13 and IL1B gene expression in chondrocytes of OA cartilage (25) and in long term cytokine-treated human primary chondrocyte cultures (22) . Although other studies have also described associations between CpG methylation status and deregulation of OA-associated genes (23, 24, 54) , this does not appear to be the case for all genes in human chondrocytes (26, 55) . However, most previous studies of OAassociated genes have investigated their CpG islands, ignoring the fact that 5Ј-UTR with non-island CpG sites may also impact functionally on gene regulation by alterations in CpG methylation status (56) . Indeed, there is a paucity of studies that have functionally analyzed alterations in promoter activity induced by the methylation of a single CpG site (6, 10, 11) . In our study, the use of a CpG-free luciferase reporter gene system (33) facilitated the investigation of the direct cause-and-effect relationships between CpG methylation and altered promoter activities of specific genes, and the dissection of the relative contribution of individual CpG sites to the transcriptional control of a given gene.
Here, we have shown that methylation of unique CpG sites in the proximal MMP13 and IL1B promoters regulates their transcriptional activities in human chondrocytes via different mechanisms (Fig. 6) . We initially quantified the methylation status of the promoters of the human genes in chondrocytes isolated from normal and OA articular cartilage and found that the Ϫ110-bp CpG and Ϫ299-bp CpG in the proximal MMP13 and IL1B promoters, respectively, were most subject to demethylation. Interestingly, 5-aza-dC treatment of human primary chondrocyte cultures induced demethylation of the same CpG sites in MMP13 and IL1B promoters, accompanied with increased expression of both genes. Although the possible involvement of other pathways in promoter-activating effects of 5-aza-dC cannot be excluded, these findings indicate that each CpG site has a different sensitivity to demethylation and that demethylation of specific CpG sites has the potential to activate or derepress MMP13 and IL1B gene expression.
We directly investigated the cause-and-effect relationship between the methylation of these specific CpG sites and the transcriptional activities of MMP13 and IL1B promoters by comparative analysis of their non-methylated and methylated forms. The activities of WT MMP13 and IL1B promoters with methylated CpG sites were reduced compared with their nonmethylated counterparts; this was true even for promoter constructs containing longer 5Ј-flanking promoter sequences, indicating that the methylation of sparse CpG sites in the proximal promoters of these two genes can have a direct suppressive effect on transcriptional activity. In addition, analyses of single and triple CpG mutants within the proximal MMP13 and IL1B promoters further clarified that their respective Ϫ110-bp CpG and Ϫ299-bp CpG sites have key roles in the methylation-dependent regulation of these two genes in human chondrocytes. Importantly, the latter specific CpG sites correspond to the most demethylated CpG sites in OA chondrocytes ex vivo and in 5-aza-dC-treated primary chondrocytes in vitro.
The Ϫ110-bp CpG and Ϫ299-bp CpG sites in the proximal promoters of the human MMP13 and IL1B genes contain putative ACGT hypoxia-responsive element consensus core sequences, which in some contexts respond to both HIF-1␣ and HIF-2␣ (57) (58) (59) (60) (61) . HIF-2␣, but not HIF-1␣, controls MMP-13 expression in chondrocytes in vitro and in vivo and regulates both endochondral ossification processes and cartilage destruction in OA disease (43, 44) . HIF-2␣, the gene product of EPAS1, is an IL-1␤-inducible member of the basic helix-loophelix Per-ARNT-Sim (bHLH-PAS) family of transcription factors that directly targets the hypoxia-responsive elements within the COL10A1, MMP13, and VEGFA promoters in chondrocytic ATDC5 cells and in HeLa cells (43) . HIF-2␣ binding to the endogenous MMP13 promoter containing the proximal hypoxia-responsive element has been demonstrated previously by ChIP in vivo and by EMSA in vitro (43) . In addition, HIF-2␣-mediated MMP13 transcriptional control has been established both in vitro and in vivo (43, 44) . Moreover, enforced expression of HIF-2␣ in vivo has been shown to result in enhanced cartilage damage in association with enhanced MMP-13 expression. Furthermore, Epas1 ϩ/Ϫ mice, which are haploinsufficient in HIF-2␣, have reduced levels of MMP13 mRNA and are resistant to surgically or chemically induced knee OA disease (44) .
Here, we have shown that enforced HIF-2␣ expression transactivates a nonmethylated WT MMP13 promoter construct and that its transactivating effect is reduced by CpG methylation. Moreover, HIF-2␣-driven MMP13 activation is solely dependent on the presence of the Ϫ110-bp CpG site in the proximal promoter of the gene and targeted methylation of the Ϫ110-bp CpG also diminishes MMP13 promoter transactivation by HIF-2␣, suggesting that demethylation of this specific CpG site is essential for HIF-2␣-mediated MMP13 promoter activation and contributes to increased MMP13 expression in OA chondrocytes. Consistent with our finding that CpG methylation treatment suppresses HIF-2␣-driven activation of the MMP13 promoter, ChIP assays performed with cells co-transfected with HIF-2␣ and a MMP13 promoter construct with a methylation-resistant reporter gene revealed that targeted methylation of the MMP13 proximal promoter significantly decreased HIF-2␣ binding affinity.
In addition to our observations, Bui et al. (10) recently reported that the same Ϫ110-bp CpG site (positioned at Ϫ104 in their report, based on the selected TSS) affects MMP13 transactivation via basal and IL1-␤-induced CREB recruitment in vitro. The latter observations, taken together with our results demonstrating that HIF-2␣-driven MMP13 control depends upon the methylation status of the Ϫ110-bp CpG site, highlight the multifaceted importance of the methylation status of this specific CpG site in the control of MMP13 transcription by different trans-acting factors responding to diverse disease-associated environmental cues and thereby revealing its potentially important role in the dysregulation of MMP13 expression observed in OA cartilage.
In contrast to the MMP13 promoter, HIF-2␣ had no activating effect on the IL1B promoter, even though the critical Ϫ299-bp CpG for IL1B promoter activity is located within a putative hypoxia-responsive element core sequence (Fig. 4D) , a non-canonical "E-box-like" sequence (CANNTG), to which several bHLH-PAS family transcription factors can bind. A heterodimer of two bHLH-PAS family members, Sim2 and ARNT, binds to non-canonical E-boxes, repressing (62, 63) or activating (64) transcription depending upon the promoter and cellular contexts. However, overexpression of Sim2 and ARNT repressed IL1B promoter activity independent of CpG methylation status. Although we found that the Ϫ299-bp CpG is essential for IL1B promoter activity and that its demethylation correlates with enhanced IL1B gene expression in human primary chondrocytes ex vivo and in vitro, mutation of this site does not attenuate IL1B promoter transactivation by NF-B. Early studies in myeloid cell lines demonstrated that two other functional NF-B sites, which exist upstream in the IL1B promoter, were influenced by CREB, whereas mutation of the Ϫ299-bp NF-B site attenuated transactivation by C/EBP␤ but not by CREB (51, 52) . Whether methylation at Ϫ299-bp CpG directly affects the binding and activities of other bHLH family members or it modulates IL1B transcription via other indirect mechanisms merits future investigation.
Our finding that methylation of the Ϫ115-bp CpG site enhances MMP13 promoter activity (Fig. 3C) , as opposed to the inhibitory effect of Ϫ110-bp CpG methylation, suggests alternative mechanisms, as reported for half-Cre sequences, where CpG methylation creates C/EBP␣ binding sites and activates gene expression (6) . The Ϫ115-bp CpG overlaps a GATA-1 binding sequence, although the inhibitory effect of GATA-1 overexpression on MMP13 promoter activity was not altered by methylation status (data not shown). Further analysis will be required to elucidate the role of the Ϫ115-bp CpG site in methylation-dependent MMP13 promoter activation.
Interestingly, treatment with 5-aza-dC in vitro produced a more marked decrease in the methylation of CpG sites in the proximal MMP13 and IL1B promoters than that observed ex vivo comparing OA and non-OA articular chondrocytes. However, whereas OA chondrocytes showed 25-fold and 800-fold MMP13 and IL1B gene expression compared with non-OA chondrocytes, the MMP13 and IL-1␤ expression levels were only modestly elevated by the more pronounced 5-aza-dC-induced demethylation in vitro. Moreover, in reporter assays, differences in promoter activities with or without methylation were also modest even when the methylation status of a specific CpG was all or none in the reporter constructs. Taken together, our observations suggest that even a small change in CpG methylation status may have a significant impact on gene expression in vivo, where CpG methylation is likely to be a contributing factor not only by altering the binding of transacting factors, but also by acting together with histone-modifying, chromatin-remodeling activities and other transcriptional regulatory elements. Indeed, 5-aza-dC treatment of primary cultures does not necessarily reflect the more complex in vivo physiological or pathological condition, where more prolonged exposure to different stimuli may induce not only differential methylation patterns but also other epigenetic changes that may be absent in our chondrocyte culture systems and reporter assays. Furthermore, analysis of the cell populations in vivo/ex vivo is limited in that cell-to-cell variability is not taken into account, whereas in vitro studies are performed with synchronized cells. Hence, limitations in current methylation and epigenomic mechanistic studies stem from the lack of technology and models that more precisely reflect the in vivo scenario. Techniques that allow for specific modulation of CpG methylation patterns in vivo are required, therefore, for a better understanding of the precise contributions of this means of transcriptional control (65, 66) .
In summary, we have investigated the relative contributions of the methylation status of individual CpG sites in the MMP13 and IL1B proximal promoters to modulation of their transcriptional activities and found that methylation of unique CpG sites has promoter-specific effects. Moreover, we show that the DNA binding and transactivation activity of HIF-2␣, a key transcription factor in MMP13 gene regulation, is prevented by methylating only one unique CpG site in the proximal MMP13 promoter. Although the use of epigenetic inhibitors as cancer therapies is closer to reality than their use in musculoskeletal diseases (67) , specific targeting of DNA methylation may eventually represent a potential therapeutic strategy to prevent or delay OA disease progression by suppressing the activities of catabolic genes causing cartilage matrix destruction. Our findings may also suggest the utility of methylation marks as advantageous early diagnostic markers of OA disease.
